Liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm study.
Dan Su, Changzheng Li, Tongsen Zheng et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, single-arm clinical study evaluated liposomal irinotecan, capecitabine, and bevacizumab as second-line therapy in patients with metastatic colorectal cancer progressing after oxaliplatin-based first-line chemotherapy. Among 63 enrolled patients, median progression-free survival was 8.1 months (95% CI, 7.3-8.9) after a median follow-up of 16.2 months. In the 48 patients with at least one tumor assessment, the objective response rate was 22.9% (11/48; 95% CI, 12.0-37.3). Grade 3 to 4 diarrhea was the most common severe adverse event, occurring in 12.7%.
Key findings
- Median progression-free survival was 8.1 months (95% CI, 7.3-8.9); median overall survival was 19.5 months (95% CI, 15.2-23.8).
- Among 48 patients assessed, objective response rate was 22.9% (11/48; 95% CI, 12.0-37.3) and disease control rate was 89.6% (43/48; 95% CI, 77.3-96.5).
- The most common grade 3 to 4 adverse events were diarrhea (12.7%), neutropenia (11.1%), and fatigue (6.3%).
Why it matters
Second-line treatment after oxaliplatin-based chemotherapy is a relevant setting in metastatic colorectal cancer. These results provide clinical activity and safety data for a three-drug regimen, including response, survival, and severe adverse-event outcomes. The findings may inform consideration of this approach, while the study design limits conclusions about comparative benefit.
What to keep in mind
The study was single-arm, so it cannot establish comparative efficacy against other second-line regimens. Tumor response estimates were based on the 48 patients who received at least one tumor assessment.